EBioMedicine - January 2020
TKM-130803 is a specific anti-EBOV therapeutic comprised of two small interfering RNAs (siRNA) siLpol-2 and siVP35-2. The pharmacokinetics (PK) of these siRNAs was defined in Ebola virus disease (EVD) patients, with reference to efficacy (ET) and toxicology thresholds (TT). The relationship between PK and patient survival was explored.
- Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review
- Clinical REsearch During Outbreaks (CREDO) Training for Low- and Middle-Income Countries
- Ethics preparedness: facilitating ethics review during outbreaks - recommendations from an expert panel